Data sharing technology company Datavant has expanded its collaboration with pharmaceutical company Boehringer Ingelheim to support Boehringer’s real-world evidence initiatives. The extended collaboration aims to leverage Datavant’s privacy-preserving tokenization and data connectivity technologies to strengthen…
Continue Reading
What You Should Know:
– Datavant, a leading health data platform, has announced an expanded collaboration with Boehringer Ingelheim to strengthen the pharmaceutical company’s real-world evidence (RWE) capabilities.
– This partnership aims to advance clinical development and commercial…
Continue Reading
Brainomix, a company offering AI-powered imaging tools for stroke and lung fibrosis, announced the completion of an $18 million Series C investment round.The round was co-led by existing investors Parkwalk Advisors and the Boehringer…
Continue Reading
This roundup is published monthly. It is meant to highlight some of healthcare’s recent hiring news and is not intended to be comprehensive. If you have news about an executive appointment, resignation or layoff…
Continue Reading
What You Should Know:
– Aignostics, a leading AI company specializing in pathology data analysis, raised $34M in Series B funding, led by ATHOS with participation from Mayo Clinic and growth financing from HTGF, alongisde…
Continue Reading
Drugmaker Boehringer Ingelheim and prescription savings platform GoodRx have teamed up to provide Boehringer’s Humira biosimilar for an exclusive cash price on GoodRx, the companies announced Thursday.
Santa Monica, California-based GoodRx helps consumers compare prescription…
Continue Reading
Patients in Widnes are benefitting from a new digital health pathway for heart health, that is designed to ensure the safety, clinical and system effectiveness of heart health apps, and the consistent distribution of…
Continue Reading
Collaborating for biologic breakthroughs, IBM and Boehringer Ingelheim merge genAI with foundation models. IBM’s cutting-edge AI expedites antibody discovery, targeting diseases like cancer, autoimmune disorders, and infections. Boehringer’s validation of refined antibodies affirms in-silico…
Continue Reading
German pharmaceutical company Boehringer Ingelheim and tech giant IBM are teaming up to harness the power of genAI and foundation models to further biologic drug discovery.The partnership leverages IBM’s foundation model technologies, consisting of…
Continue Reading
What You Should Know:
– Boehringer Ingelheim and IBM announced a collaboration to leverage IBM’s foundation model technologies for the discovery of novel candidate antibodies in drug development.
– The partnership will focus on utilizing IBM’s…
Continue Reading
